FIBROBLAST GROWTH FACTOR AND BONE RESORPTION IN PATIENTS WITH BREAST CANCER

乳腺癌患者的成纤维细胞生长因子和骨吸收

• 批准号: 6122693
• 负责人: JONATHAN R SPORN
• 金额: $ 1.91万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122693
• 关键词: adenocarcinoma; antineoplastics; bone neoplasms; breast neoplasms; clinical research; female; fibroblast growth factor; human subject; human therapy evaluation; metastasis; physiologic bone resorption; serology /serodiagnosis

This project will measure Fibroblast Growth Factor (FGF) levels in patients with breast cancer and their possible effects on bone metastasis. The investigators hypothesize that 1) serum FGF levels in patients with adenocarcinoma of the breast are greater in those with bone metastasis in comparison to those without bone metastasis and normal volunteers. This difference is due to the release of FGF-2 from resorbing bone, and, 2) that pamidronate therapy in patients with bone metastasis will decrease the serum levels of FGF by inhibiting bone resorption.

该项目将测量乳腺癌患者的成纤维细胞生长因子（FGF）水平及其对骨转移的可能影响。 研究人员假设：1）与无骨转移的患者和正常志愿者相比，乳腺癌患者中骨转移患者的血清FGF水平更高。 这种差异是由于FGF-2从再吸收骨中释放，以及2）骨转移患者的帕米膦酸盐治疗将通过抑制骨再吸收降低FGF的血清水平。